- Home
- SLG vs AAPG Comparison
SLG vs AAPG Comparison
Compare SLG & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLG
- AAPG
- Stock Information
- Founded
- SLG 1980
- AAPG 2009
- Country
- SLG United States
- AAPG China
- Employees
- SLG N/A
- AAPG N/A
- Industry
- SLG Real Estate Investment Trusts
- AAPG Biotechnology: Pharmaceutical Preparations
- Sector
- SLG Real Estate
- AAPG Health Care
- Exchange
- SLG Nasdaq
- AAPG Nasdaq
- Market Cap
- SLG 4.0B
- AAPG 3.6B
- IPO Year
- SLG 1997
- AAPG 2025
- Fundamental
- Price
- SLG $65.67
- AAPG $40.54
- Analyst Decision
- SLG Hold
- AAPG Buy
- Analyst Count
- SLG 16
- AAPG 1
- Target Price
- SLG $67.56
- AAPG N/A
- AVG Volume (30 Days)
- SLG 905.5K
- AAPG 11.7K
- Earning Date
- SLG 10-15-2025
- AAPG 11-06-2025
- Dividend Yield
- SLG 4.71%
- AAPG N/A
- EPS Growth
- SLG N/A
- AAPG N/A
- EPS
- SLG N/A
- AAPG N/A
- Revenue
- SLG $640,547,000.00
- AAPG $54,524,554.00
- Revenue This Year
- SLG N/A
- AAPG N/A
- Revenue Next Year
- SLG $1.92
- AAPG $387.72
- P/E Ratio
- SLG N/A
- AAPG N/A
- Revenue Growth
- SLG N/A
- AAPG N/A
- 52 Week Low
- SLG $45.15
- AAPG $16.50
- 52 Week High
- SLG $82.81
- AAPG $48.45
- Technical
- Relative Strength Index (RSI)
- SLG 71.05
- AAPG N/A
- Support Level
- SLG $59.12
- AAPG N/A
- Resistance Level
- SLG $62.20
- AAPG N/A
- Average True Range (ATR)
- SLG 1.51
- AAPG 0.00
- MACD
- SLG 0.94
- AAPG 0.00
- Stochastic Oscillator
- SLG 95.63
- AAPG 0.00
About SLG SL Green Realty Corp
SL Green Realty is one of the largest Manhattan property owners and landlords, with interest in around 32 million square feet of wholly owned and joint-venture office space. The company has additional property exposure through its limited portfolio of well-located retail space. It operates as a real estate investment trust.
About AAPG Ascentage Pharma Group International American Depository Shares
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.